Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

A Rapid Qualitative Review of Sarcoidosis: Clinical Manifestations, Immunopathogenesis, Diagnosis and Treatment

Author(s): Shahab Shahgaldi , Ardeshir Abbasi * and Nasim Rahmani-Kukia

Volume 22, Issue 12, 2022

Published on: 05 January, 2022

Page: [1619 - 1630] Pages: 12

DOI: 10.2174/1389557521666211013112211

Price: $65

Abstract

Sarcoidosis is a worldwide inflammatory disorder of unknown etiology that is characterized by the formation of non-caseatingimmune granulomas in involved organs,most commonly in the lungs and eyes. Although clinical manifestations of sarcoidosis depend on the organs involved, the most common symptoms include fatigue, fever, weight loss, eye pain, dyspnea, and chest pain. Sarcoidosis usually undergoes spontaneous regression, yet its chronic form progressively threatens the involved organs through the induction of fibrotic damage. Despite decades of medical research, the etiology of sarcoidosis still remains unclear. Nevertheless, a combination of contributors, including genetic factors, environmental exposures, and microbial agents, is believed to trigger the inflammatory state observed in this disease. Furthermore, a highly polarized Th1 and Th17 response with diminished immunomodulatory mechanisms constitute the most significant immunological event associated with this disorder. Indeed, sarcoid granulomas, which consist of highly activated antigen-presenting cells (APCs) and lymphocytes, maintain a robust specialized niche to facilitate antigen presentation and exaggerated immune responses. Both the unknown etiology and multisystem nature of the disease have hampered the development of specific therapeutics and definitive diagnostic assays for sarcoidosis. Consequently, its diagnosis and treatment still represent a challenging task for clinicians. In this article, we aim to summarize contemporary findings of sarcoidosis and its etiology, pathogenesis, and treatment.

Keywords: Sarcoidosis, granuloma, inflammatory diseases, inflammation, immune cell, APC.

« Previous Next »
Graphical Abstract

[1]
Hunninghake, G.; Costabel, U.; Ando, M.; Baughman, R.; Cordier, J. Du Bois, R American Thoracic Society/European Respiratory So-ciety/World Association of Sarcoidosis and other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases: Off. J. WASOG, 1999, 16(2), 149.
[2]
Sharma, O.P. Murray Kornfeld, American College Of Chest Physician, and sarcoidosis: A historical footnote: 2004 Murray Kornfeld Me-morial Founders Lecture. Chest, 2005, 128(3), 1830-1835.
[http://dx.doi.org/10.1016/S0012-3692(15)52223-X] [PMID: 16162793]
[3]
King, T. Jr Sarcoidosis: interstitial lung diseases: Merck manual home edition; The Merck Manual Home Edition Merck Sharp & Dohme Corp., 2008.
[4]
James, D.G.; Sharma, O.P. From Hutchinson to now: A historical glimpse. Curr. Opin. Pulm. Med., 2002, 8(5), 416-423.
[http://dx.doi.org/10.1097/00063198-200209000-00013] [PMID: 12172446]
[5]
Rheumatologic manifestations of sarcoidosis.Sweiss, N.J.; Patterson, K.; Sawaqed, R.; Jabbar, U.; Korsten, P.; Hogarth, K., Eds.; Seminars in respiratory and critical care medicine; Thieme Medical Publishers, 2010..
[http://dx.doi.org/10.1055/s-0030-1262214]
[6]
Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053), 1459-1544.
[http://dx.doi.org/10.1016/S0140-6736(16)31012-1] [PMID: 27733281]
[7]
Vos, T.; Abajobir, A.A.; Abate, K.H.; Abbafati, C.; Abbas, K.M.; Abd-Allah, F. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Di-sease Study 2016. Lancet, 2017, 390(10100), 1211-1259.
[http://dx.doi.org/10.1016/S0140-6736(17)32154-2] [PMID: 28919117]
[8]
Judson, M.A. Corticosteroids in sarcoidosis. Rheumatic Disease Clinics., 2016, 42(1), 119-135. ,ix.
[http://dx.doi.org/10.1016/j.rdc.2015.08.012] [PMID: 26611555]
[9]
Moller, D.R.; Chen, E.S. Genetic basis of remitting sarcoidosis: Triumph of the trimolecular complex? Am. J. Respir. Cell Mol. Biol., 2002, 27(4), 391-395.
[http://dx.doi.org/10.1165/rcmb.2002-0164PS] [PMID: 12356571]
[10]
Grunewald, J.; Eklund, A. Löfgren’s syndrome: Human leukocyte antigen strongly influences the disease course. Am. J. Respir. Crit. Care Med., 2009, 179(4), 307-312.
[http://dx.doi.org/10.1164/rccm.200807-1082OC] [PMID: 18996998]
[11]
Ungprasert, P.; Crowson, C.S.; Matteson, E.L. Epidemiology and clinical characteristics of sarcoidosis: An update from a population-based cohort study from Olmsted County, Minnesota. Reumatismo, 2017, 69(1), 16-22.
[http://dx.doi.org/10.4081/reumatismo.2017.965] [PMID: 28535617]
[12]
Hu, X.; Carmona, EM.; Yi, ES.; Pellikka, PA.; Ryu, J. Causes of death in patients with chronic sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases: Off. J. WASOG, 2016, 33(3), 275-280.
[13]
Baughman, R.P.; Teirstein, A.S.; Judson, M.A.; Rossman, M.D.; Yeager, H., Jr; Bresnitz, E.A.; DePalo, L.; Hunninghake, G.; Iannuzzi, M.C.; Johns, C.J.; McLennan, G.; Moller, D.R.; Newman, L.S.; Rabin, D.L.; Rose, C.; Rybicki, B.; Weinberger, S.E.; Terrin, M.L.; Knat-terud, G.L.; Cherniak, R. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care Med., 2001, 164(10 Pt 1), 1885-1889.
[http://dx.doi.org/10.1164/ajrccm.164.10.2104046] [PMID: 11734441]
[14]
Spagnolo, P.; Rossi, G.; Trisolini, R.; Sverzellati, N.; Baughman, R.P.; Wells, A.U. Pulmonary sarcoidosis. Lancet Respir. Med., 2018, 6(5), 389-402.
[http://dx.doi.org/10.1016/S2213-2600(18)30064-X] [PMID: 29625772]
[15]
Tavana, S.; Alizadeh, M.; Mohajerani, SA.; Hashemian, SM. Pulmonary and extra-pulmonary manifestations of sarcoidosis. Nigerian Med. J.: J. Nigeria Med. Associat., 2015, 56(4), 258.
[16]
Kansal, V; Dollin, M Ocular involvement in sarcoidosis., CMAJ, 2017, 189(16), E609-E..
[http://dx.doi.org/10.1503/cmaj.160569]
[17]
Raevis, J.J.; Antonova, N.; Agemy, S. Ocular involvement in sarcoidosis. J. Rheumatol., 2018, 45(4), 580.
[http://dx.doi.org/10.3899/jrheum.171058] [PMID: 29606646]
[18]
Prystowsky, S.; Sanchez, M. Cutaneous manifestations of sarcoidosis; Melin, J.A., Ed.; , 2017.
[19]
Birnie, D.H.; Kandolin, R.; Nery, P.B.; Kupari, M. Cardiac manifestations of sarcoidosis: Diagnosis and management. Eur. Heart J., 2017, 38(35), 2663-2670.
[PMID: 27469375]
[20]
Shah, N.; Mitra, A. Gastrointestinal and hepatic sarcoidosis: A review article. Clin. Liver Dis. (Hoboken), 2021, 17(4), 301-307.
[http://dx.doi.org/10.1002/cld.1055] [PMID: 33968393]
[21]
Zhou, Y.; Lower, E.E.; Li, H.; Farhey, Y.; Baughman, R.P., Eds.; Clinical characteristics of patients with bone sarcoidosis. Seminars in arthritis and rheumatism; Elsevier, 2017.
[22]
Ibitoye, R.T.; Wilkins, A.; Scolding, N.J. Neurosarcoidosis: A clinical approach to diagnosis and management. J. Neurol., 2017, 264(5), 1023-1028.
[http://dx.doi.org/10.1007/s00415-016-8336-4] [PMID: 27878437]
[23]
Correia, F.A.S.C.; Marchini, G.S.; Torricelli, F.C.; Danilovic, A.; Vicentini, F.C.; Srougi, M.; Nahas, W.C.; Mazzucchi, E. Renal manifesta-tions of sarcoidosis: From accurate diagnosis to specific treatment. Int. Braz J Urol, 2020, 46(1), 15-25.
[http://dx.doi.org/10.1590/s1677-5538.ibju.2019.0042] [PMID: 31851454]
[24]
Karakaya, B.; Kaiser, Y.; van Moorsel, C.H.; Grunewald, J., Eds.; Löfgren’s syndrome: diagnosis, management, and disease pathogenesis. Seminars in respiratory and critical care medicine; Thieme Medical Publishers, 2017.
[25]
Ungprasert, P.; Ryu, J.H.; Matteson, E.L. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin. Proc. Innov. Qual. Outcomes, 2019, 3(3), 358-375.
[http://dx.doi.org/10.1016/j.mayocpiqo.2019.04.006] [PMID: 31485575]
[26]
Shahgaldi, S; Abbasi, A; Rahmani-Kukia, N; Ahmadzadeh, A; Sabeti, S. Coexistence of Parathyroid Adenoma, Sarcoidosis, and Hypercalcemia. JCR: J. Clin. Rheumatol.,. 2021.
[27]
Judson, M.A. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep., 2014, 6, 89.
[http://dx.doi.org/10.12703/P6-89] [PMID: 25374667]
[28]
Valeyre, D.; Prasse, A.; Nunes, H.; Uzunhan, Y.; Brillet, P.Y.; Müller-Quernheim, J. Sarcoidosis. Lancet, 2014, 383(9923), 1155-1167.
[http://dx.doi.org/10.1016/S0140-6736(13)60680-7] [PMID: 24090799]
[29]
Kikuchi, H.; Mori, T.; Rai, T.; Uchida, S. Acute kidney injury caused by sarcoid granulomatous interstitial nephritis without extrarenal manifestations. CEN Case Rep., 2015, 4(2), 212-217.
[http://dx.doi.org/10.1007/s13730-015-0171-4] [PMID: 28509105]
[30]
Chopra, A.; Kalkanis, A.; Judson, M.A. Biomarkers in sarcoidosis. Expert Rev. Clin. Immunol., 2016, 12(11), 1191-1208.
[http://dx.doi.org/10.1080/1744666X.2016.1196135] [PMID: 27253883]
[31]
Shah, K.K.; Pritt, B.S.; Alexander, M.P. Histopathologic review of granulomatous inflammation. J. Clin. Tuberc. Other Mycobact. Dis., 2017, 7, 1-12.
[http://dx.doi.org/10.1016/j.jctube.2017.02.001] [PMID: 31723695]
[32]
Smith, J.K.; Matheus, M.G.; Castillo, M. Imaging manifestations of neurosarcoidosis. Am. J. Roentgenol., 2004, 182(2), 289-295.
[http://dx.doi.org/10.2214/ajr.182.2.1820289] [PMID: 14736648]
[33]
Huang, J.F.; Aksamit, A.J.; Staff, N.P. MRI and PET imaging discordance in neurosarcoidosis. Neurology, 2012, 79(10), 1070.
[http://dx.doi.org/10.1212/WNL.0b013e3182684672] [PMID: 22946115]
[34]
Smith-Rohrberg, D.; Sharma, S.K. Tuberculin skin test among pulmonary sarcoidosis patients with and without tuberculosis: Its utility for the screening of the two conditions in tuberculosis-endemic regions. Sarcoidosis Vasc. Diffuse Lung Dis., 2006, 23(2), 130-134.
[PMID: 17937109]
[35]
Kraaijvanger, R.; Janssen Bonás, M.; Vorselaars, A.D.M.; Veltkamp, M. Biomarkers in the diagnosis and prognosis of sarcoidosis: Cu-rrent use and future prospects. Front. Immunol., 2020, 11, 1443.
[http://dx.doi.org/10.3389/fimmu.2020.01443] [PMID: 32760396]
[36]
Role of genetics in susceptibility and outcome of sarcoidosis. In: Grunewald, J., EdSeminars in respiratory and critical care medicine; Thieme Medical Publishers, 2010.
[37]
Müller-Quernheim, J.; Prasse, A.; Zissel, G. Pathogenesis of sarcoidosis. Presse Med., 2012, 41(6 Pt 2), e275-e287.
[http://dx.doi.org/10.1016/j.lpm.2012.03.018] [PMID: 22595775]
[38]
Dubaniewicz, A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun. Rev., 2010, 9(6), 419-424.
[http://dx.doi.org/10.1016/j.autrev.2009.11.015] [PMID: 19931650]
[39]
Judson, M.A.; Boan, A.D.; Lackland, D.T. The clinical course of sarcoidosis: Presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc. Diffuse Lung Dis., 2012, 29(2), 119-127.
[PMID: 23461074]
[40]
Kobak, S; Yilmaz, H; Sever, F; Duran, A; Sen, N; Karaarslan, A The prevalence of antinuclear antibodies in patients with sarcoidosis., Autoimmune Dis., 2014, 2014..
[http://dx.doi.org/10.1155/2014/351852]
[41]
Chen, E.S.; Moller, D.R. Etiology of sarcoidosis. Clin. Chest Med., 2008, 29(3), 365-377. [vii.
[http://dx.doi.org/10.1016/j.ccm.2008.03.011] [PMID: 18539232]
[42]
Ahlgren, K.M.; Ruckdeschel, T.; Eklund, A.; Wahlström, J.; Grunewald, J. T cell receptor-Vβ repertoires in lung and blood CD4+ and CD8+ T cells of pulmonary sarcoidosis patients. BMC Pulm. Med., 2014, 14(1), 50.
[http://dx.doi.org/10.1186/1471-2466-14-50] [PMID: 24656074]
[43]
Coulombe, P.A.; Wong, P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat. Cell Biol., 2004, 6(8), 699-706.
[http://dx.doi.org/10.1038/ncb0804-699] [PMID: 15303099]
[44]
Linke, M.; Pham, H.T.T.; Katholnig, K.; Schnöller, T.; Miller, A.; Demel, F.; Schütz, B.; Rosner, M.; Kovacic, B.; Sukhbaatar, N.; Niede-rreiter, B.; Blüml, S.; Kuess, P.; Sexl, V.; Müller, M.; Mikula, M.; Weckwerth, W.; Haschemi, A.; Susani, M.; Hengstschläger, M.; Gambe-llo, M.J.; Weichhart, T. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat. Immunol., 2017, 18(3), 293-302.
[http://dx.doi.org/10.1038/ni.3655] [PMID: 28092373]
[45]
Heckmann, J.G.; Stefan, H.; Heuss, D.; Hopp, P.; Neundörfer, B. Isolated muscular sarcoidosis. Eur. J. Neurol., 2001, 8(4), 365-366.
[http://dx.doi.org/10.1046/j.1468-1331.2001.00229.x] [PMID: 11422437]
[46]
Heyder, T.; Kohler, M.; Tarasova, N.K.; Haag, S.; Rutishauser, D.; Rivera, N.V.; Sandin, C.; Mia, S.; Malmström, V.; Wheelock, Å.M.; Wahlström, J.; Holmdahl, R.; Eklund, A.; Zubarev, R.A.; Grunewald, J.; Ytterberg, A.J. Approach for identifying human leukocyte antigen (HLA)-DR bound peptides from scarce clinical samples. Mol. Cell. Proteomics, 2016, 15(9), 3017-3029.
[http://dx.doi.org/10.1074/mcp.M116.060764] [PMID: 27452731]
[47]
Ten Berge, B.; Paats, M.S.; Bergen, I.M.; van den Blink, B.; Hoogsteden, H.C.; Lambrecht, B.N.; Hendriks, R.W.; Kleinjan, A. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford), 2012, 51(1), 37-46.
[http://dx.doi.org/10.1093/rheumatology/ker316] [PMID: 22075064]
[48]
Broos, C.E.; van Nimwegen, M.; Hoogsteden, H.C.; Hendriks, R.W.; Kool, M.; van den Blink, B. Granuloma formation in pulmonary sar-coidosis. Front. Immunol., 2013, 4, 437.
[http://dx.doi.org/10.3389/fimmu.2013.00437] [PMID: 24339826]
[49]
Facco, M.; Cabrelle, A.; Teramo, A.; Olivieri, V.; Gnoato, M.; Teolato, S.; Ave, E.; Gattazzo, C.; Fadini, G.P.; Calabrese, F.; Semenzato, G.; Agostini, C. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, 66(2), 144-150.
[http://dx.doi.org/10.1136/thx.2010.140319] [PMID: 21139119]
[50]
Ten Berge, B.; Kleinjan, A.; Muskens, F.; Hammad, H.; Hoogsteden, H.C.; Hendriks, R.W.; Lambrecht, B.N.; Van den Blink, B. Evidence for local dendritic cell activation in pulmonary sarcoidosis. Respir. Res., 2012, 13(1), 33.
[http://dx.doi.org/10.1186/1465-9921-13-33] [PMID: 22513006]
[51]
Koth, L.L.; Solberg, O.D.; Peng, J.C.; Bhakta, N.R.; Nguyen, C.P.; Woodruff, P.G. Sarcoidosis blood transcriptome reflects lung inflamma-tion and overlaps with tuberculosis. Am. J. Respir. Crit. Care Med., 2011, 184(10), 1153-1163.
[http://dx.doi.org/10.1164/rccm.201106-1143OC] [PMID: 21852540]
[52]
Ardura, J.A.; Rackov, G.; Izquierdo, E.; Alonso, V.; Gortazar, A.R.; Escribese, M.M. Targeting macrophages: Friends or foes in disease? Front. Pharmacol., 2019, 10, 1255.
[http://dx.doi.org/10.3389/fphar.2019.01255] [PMID: 31708781]
[53]
Shapouri-Moghaddam, A.; Mohammadian, S.; Vazini, H.; Taghadosi, M.; Esmaeili, S.A.; Mardani, F.; Seifi, B.; Mohammadi, A.; Afshari, J.T.; Sahebkar, A. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol., 2018, 233(9), 6425-6440.
[http://dx.doi.org/10.1002/jcp.26429] [PMID: 29319160]
[54]
Chen, E.S.; Moller, D.R. Sarcoidosis--scientific progress and clinical challenges. Nat. Rev. Rheumatol., 2011, 7(8), 457-467.
[http://dx.doi.org/10.1038/nrrheum.2011.93] [PMID: 21750528]
[55]
Ziegenhagen, M.; Rothe, M.; Zissel, G.; Müller-Quernheim, J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resis-tant sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases: Off. J. WASOG, 2002, 19(3), 185-190.
[56]
Pozzi, L-A.M.; Maciaszek, J.W.; Rock, K.L. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol., 2005, 175(4), 2071-2081.
[http://dx.doi.org/10.4049/jimmunol.175.4.2071] [PMID: 16081773]
[57]
Ostadkarampour, M.; Eklund, A.; Moller, D.; Glader, P.; Olgart Höglund, C.; Lindén, A.; Grunewald, J.; Wahlström, J. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren’s syndrome. Clin. Exp. Immunol., 2014, 178(2), 342-352.
[http://dx.doi.org/10.1111/cei.12403] [PMID: 24962673]
[58]
Okamoto Yoshida, Y.; Umemura, M.; Yahagi, A.; O’Brien, R.L.; Ikuta, K.; Kishihara, K.; Hara, H.; Nakae, S.; Iwakura, Y.; Matsuzaki, G. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol., 2010, 184(8), 4414-4422.
[http://dx.doi.org/10.4049/jimmunol.0903332] [PMID: 20212094]
[59]
Huitema, M.P.; Spee, M.; Vorselaars, V.M.; Boerman, S.; Snijder, R.J.; van Es, H.W.; Reesink, H.J.; Grutters, J.C.; Post, M.C. Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur. Respir. J., 2016, 47(2), 673-676.
[http://dx.doi.org/10.1183/13993003.01319-2015] [PMID: 26493790]
[60]
Broos, C.E.; Koth, L.L.; van Nimwegen, M. In ’t Veen, J.C.C.M.; Paulissen, S.M.J.; van Hamburg, J.P.; Annema, J.T.; Heller-Baan, R.; Kleinjan, A.; Hoogsteden, H.C.; Wijsenbeek, M.S.; Hendriks, R.W.; van den Blink, B.; Kool, M. Increased T-helper 17.1 cells in sarcoido-sis mediastinal lymph nodes. Eur. Respir. J., 2018, 51(3), 1701124.
[http://dx.doi.org/10.1183/13993003.01124-2017] [PMID: 29449421]
[61]
Chen, E.S.; Song, Z.; Willett, M.H.; Heine, S.; Yung, R.C.; Liu, M.C.; Groshong, S.D.; Zhang, Y.; Tuder, R.M.; Moller, D.R. Serum amy-loid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am. J. Respir. Crit. Care Med., 2010, 181(4), 360-373.
[http://dx.doi.org/10.1164/rccm.200905-0696OC] [PMID: 19910611]
[62]
Wikén, M.; Grunewald, J.; Eklund, A.; Wahlström, J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J. Clin. Immunol., 2009, 29(1), 78-89.
[http://dx.doi.org/10.1007/s10875-008-9225-0] [PMID: 18773284]
[63]
Miedema, J.R.; Kaiser, Y.; Broos, C.E.; Wijsenbeek, M.S.; Grunewald, J.; Kool, M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren’s syndrome: Friend or foe? J. Autoimmun., 2018, 87, 82-96.
[http://dx.doi.org/10.1016/j.jaut.2017.12.012] [PMID: 29310925]
[64]
Chu, W-M. Tumor necrosis factor. Cancer Lett., 2013, 328(2), 222-225.
[http://dx.doi.org/10.1016/j.canlet.2012.10.014] [PMID: 23085193]
[65]
Sasaki, M.; Namioka, Y.; Ito, T.; Izumiyama, N.; Fukui, S.; Watanabe, A.; Kashima, M.; Sano, M.; Shioya, T.; Miura, M. Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-α and INF-γ. Mediators Inflamm., 2001, 10(6), 309-313.
[http://dx.doi.org/10.1080/09629350120102325] [PMID: 11817671]
[66]
Grunewald, J.; Kaiser, Y.; Ostadkarampour, M.; Rivera, N.V.; Vezzi, F.; Lötstedt, B.; Olsen, R.A.; Sylwan, L.; Lundin, S.; Käller, M.; San-dalova, T.; Ahlgren, K.M.; Wahlström, J.; Achour, A.; Ronninger, M.; Eklund, A. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur. Respir. J., 2016, 47(3), 898-909.
[http://dx.doi.org/10.1183/13993003.01209-2015] [PMID: 26585430]
[67]
Kinloch, A.J.; Kaiser, Y.; Wolfgeher, D.; Ai, J.; Eklund, A.; Clark, M.R.; Grunewald, J. In situ humoral immunity to vimentin in HLA-DRB1* 03+ patients with pulmonary sarcoidosis. Front. Immunol., 2018, 9, 1516.
[http://dx.doi.org/10.3389/fimmu.2018.01516] [PMID: 30038611]
[68]
Bhaumik, S.; Basu, R. Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. Front. Immunol., 2017, 8, 254.
[http://dx.doi.org/10.3389/fimmu.2017.00254] [PMID: 28408906]
[69]
Rosenbaum, J.T.; Pasadhika, S.; Crouser, E.D.; Choi, D.; Harrington, C.A.; Lewis, J.A.; Austin, C.R.; Diebel, T.N.; Vance, E.E.; Braziel, R.M.; Smith, J.R.; Planck, S.R. Hypothesis: Sarcoidosis is a STAT1-mediated disease. Clin. Immunol., 2009, 132(2), 174-183.
[http://dx.doi.org/10.1016/j.clim.2009.04.010] [PMID: 19464956]
[70]
Li, H.; Zhao, X.; Wang, J.; Zong, M.; Yang, H. Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. Gene, 2017, 596, 98-104.
[http://dx.doi.org/10.1016/j.gene.2016.09.037] [PMID: 27682024]
[71]
Zhou, T.; Casanova, N.; Pouladi, N.; Wang, T.; Lussier, Y.; Knox, K.S.; Garcia, J.G.N. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci. Rep., 2017, 7(1), 4237.
[http://dx.doi.org/10.1038/s41598-017-04109-6] [PMID: 28652588]
[72]
Agostini, C.; Cabrelle, A.; Calabrese, F.; Bortoli, M.; Scquizzato, E.; Carraro, S.; Miorin, M.; Beghè, B.; Trentin, L.; Zambello, R.; Facco, M.; Semenzato, G. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am. J. Respir. Crit. Care Med., 2005, 172(10), 1290-1298.
[http://dx.doi.org/10.1164/rccm.200501-142OC] [PMID: 16100013]
[73]
Roach, D.R.; Bean, A.G.; Demangel, C.; France, M.P.; Briscoe, H.; Britton, W.J. TNF regulates chemokine induction essential for cell re-cruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol., 2002, 168(9), 4620-4627.
[http://dx.doi.org/10.4049/jimmunol.168.9.4620] [PMID: 11971010]
[74]
Miyara, M.; Amoura, Z.; Parizot, C.; Badoual, C.; Dorgham, K.; Trad, S.; Kambouchner, M.; Valeyre, D.; Chapelon-Abric, C.; Debré, P.; Piette, J.C.; Gorochov, G. The immune paradox of sarcoidosis and regulatory T cells. J. Exp. Med., 2006, 203(2), 359-370.
[http://dx.doi.org/10.1084/jem.20050648] [PMID: 16432251]
[75]
Abel, A.M.; Yang, C.; Thakar, M.S.; Malarkannan, S. Natural killer cells: Development, maturation, and clinical utilization. Front. Immunol., 2018, 9, 1869.
[http://dx.doi.org/10.3389/fimmu.2018.01869] [PMID: 30150991]
[76]
Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. Nat. Immunol., 2008, 9(5), 503-510.
[http://dx.doi.org/10.1038/ni1582] [PMID: 18425107]
[77]
Guglani, L.; Khader, S.A. Th17 cytokines in mucosal immunity and inflammation. Curr. Opin. HIV AIDS, 2010, 5(2), 120-127.
[http://dx.doi.org/10.1097/COH.0b013e328335c2f6] [PMID: 20543588]
[78]
Shen, H.; Chen, Z.W. The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection. Cell. Mol. Immunol., 2018, 15(3), 216-225.
[http://dx.doi.org/10.1038/cmi.2017.128] [PMID: 29176747]
[79]
Celada, L.J.; Kropski, J.A.; Herazo-Maya, J.D.; Luo, W.; Creecy, A.; Abad, A.T.; Chioma, O.S.; Lee, G.; Hassell, N.E.; Shaginurova, G.I.; Wang, Y.; Johnson, J.E.; Kerrigan, A.; Mason, W.R.; Baughman, R.P.; Ayers, G.D.; Bernard, G.R.; Culver, D.A.; Montgomery, C.G.; Maher, T.M.; Molyneaux, P.L.; Noth, I.; Mutsaers, S.E.; Prele, C.M.; Peebles, R.S., Jr; Newcomb, D.C.; Kaminski, N.; Blackwell, T.S.; Van Kaer, L.; Drake, W.P. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci. Transl. Med., 2018, 10(460), eaar8356.
[http://dx.doi.org/10.1126/scitranslmed.aar8356] [PMID: 30257954]
[80]
Damsky, W.; Thakral, D.; McGeary, M.K.; Leventhal, J.; Galan, A.; King, B. Janus kinase inhibition induces disease remission in cuta-neous sarcoidosis and granuloma annulare. J. Am. Acad. Dermatol., 2020, 82(3), 612-621.
[http://dx.doi.org/10.1016/j.jaad.2019.05.098] [PMID: 31185230]
[81]
Rottenberg, M.E.; Carow, B., Eds.; SOCS3 and STAT3, major controllers of the outcome of infection with Mycobacterium tuberculosis. Seminars in immunology; Elsevier, 2014.
[82]
Zhao, H.; Liao, X.; Kang, Y. Tregs: Where we are and what comes next? Front. Immunol., 2017, 8, 1578.
[http://dx.doi.org/10.3389/fimmu.2017.01578] [PMID: 29225597]
[83]
Perdigoto, A.L.; Chatenoud, L.; Bluestone, J.A.; Herold, K.C. Inducing and administering tregs to treat human disease. Front. Immunol., 2016, 6, 654.
[http://dx.doi.org/10.3389/fimmu.2015.00654] [PMID: 26834735]
[84]
Sharma, A.; Rudra, D. Emerging functions of regulatory T cells in tissue homeostasis. Front. Immunol., 2018, 9, 883.
[http://dx.doi.org/10.3389/fimmu.2018.00883] [PMID: 29887862]
[85]
Crouser, E.D. Role of imbalance between Th17 and regulatory T-cells in sarcoidosis. Curr. Opin. Pulm. Med., 2018, 24(5), 521-526.
[http://dx.doi.org/10.1097/MCP.0000000000000498] [PMID: 29985180]
[86]
Kaiser, Y.; Eklund, A.; Grunewald, J. Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder. Eur. Respir. J., 2019, 54(1), 1802153.
[http://dx.doi.org/10.1183/13993003.021532018] [PMID: 31000677]
[87]
Krovi, S.H.; Gapin, L. Invariant natural killer T Cell subsets-more than just developmental intermediates. Front. Immunol., 2018, 9, 1393.
[http://dx.doi.org/10.3389/fimmu.2018.01393] [PMID: 29973936]
[88]
Yamaura, A.; Hotta, C.; Nakazawa, M.; Van Kaer, L.; Minami, M. Human invariant Valpha24+ natural killer T cells acquire regulatory functions by interacting with IL-10-treated dendritic cells. Blood, 2008, 111(8), 4254-4263.
[http://dx.doi.org/10.1182/blood-2007-04-085142] [PMID: 18270329]
[89]
Taflin, C.; Miyara, M.; Nochy, D.; Valeyre, D.; Naccache, J-M.; Altare, F.; Salek-Peyron, P.; Badoual, C.; Bruneval, P.; Haroche, J.; Mat-hian, A.; Amoura, Z.; Hill, G.; Gorochov, G. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am. J. Pathol., 2009, 174(2), 497-508.
[http://dx.doi.org/10.2353/ajpath.2009.080580] [PMID: 19147826]
[90]
Starshinova, A.A.; Malkova, A.M.; Basantsova, N.Y.; Zinchenko, Y.S.; Kudryavtsev, I.V.; Ershov, G.A.; Soprun, L.A.; Mayevskaya, V.A.; Churilov, L.P.; Yablonskiy, P.K. Sarcoidosis as an autoimmune disease. Front. Immunol., 2020, 10, 2933.
[http://dx.doi.org/10.3389/fimmu.2019.02933] [PMID: 31969879]
[91]
Locke, L.W.; Crouser, E.D.; White, P.; Julian, M.W.; Caceres, E.G.; Papp, A.C.; Le, V.T.; Sadee, W.; Schlesinger, L.S. IL-13–regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am. J. Respir. Cell Mol. Biol., 2019, 60(1), 84-95.
[http://dx.doi.org/10.1165/rcmb.2018-0053OC] [PMID: 30134122]
[92]
Prasse, A.; Pechkovsky, D.V.; Toews, G.B.; Jungraithmayr, W.; Kollert, F.; Goldmann, T.; Vollmer, E.; Müller-Quernheim, J.; Zissel, G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med., 2006, 173(7), 781-792.
[http://dx.doi.org/10.1164/rccm.200509-1518OC] [PMID: 16415274]
[93]
Pereira, C.A.; Dornfeld, M.C.; Baughman, R.; Judson, M.A. Clinical phenotypes in sarcoidosis. Curr. Opin. Pulm. Med., 2014, 20(5), 496-502.
[http://dx.doi.org/10.1097/MCP.0000000000000077] [PMID: 25035964]
[94]
James, W.E.; Baughman, R. Treatment of sarcoidosis: Grading the evidence. Expert Rev. Clin. Pharmacol., 2018, 11(7), 677-687.
[http://dx.doi.org/10.1080/17512433.2018.1486706] [PMID: 29883224]
[95]
Iriarte, A.; Rubio-Rivas, M.; Villalba, N.; Corbella, X.; Mañá, J. Clinical features and outcomes of asymptomatic pulmonary sarcoidosis. A comparative cohort study. Respir. Med., 2020, 169, 105998.
[http://dx.doi.org/10.1016/j.rmed.2020.105998] [PMID: 32442109]
[96]
Zisman, D.A.; Shorr, A.F.; Lynch Iii, J.P., Eds.; Sarcoidosis involving the musculoskeletal system. Seminars in respiratory and critical care medicine; Thieme Medical Publishers, Inc.: 333 Seventh Avenue,, 2002, 23, pp. (6)555-570.
[http://dx.doi.org/10.1055/s-2002-36520]
[97]
Baughman, R.P.; Judson, M.A.; Wells, A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasc. Diffuse Lung Dis., 2017, 34(4), 280-282.
[PMID: 32476859]
[98]
Nunes, H.; Jeny, F.; Bouvry, D.; Uzunhan, Y.; Valeyre, D. Indications for treatment of sarcoidosis. Curr. Opin. Pulm. Med., 2019, 25(5), 505-518.
[http://dx.doi.org/10.1097/MCP.0000000000000604] [PMID: 31365385]
[99]
Valeyre, D.; Jeny, F.; Nunes, H., Eds.; Current medical therapy for sarcoidosis. Seminars in respiratory and critical care medicine; Thieme Medical Publishers, 2017.
[100]
El Jammal, T.; Jamilloux, Y.; Gerfaud-Valentin, M.; Valeyre, D.; Sève, P. Refractory sarcoidosis: A review. Ther. Clin. Risk Manag., 2020, 16, 323-345.
[http://dx.doi.org/10.2147/TCRM.S192922] [PMID: 32368072]
[101]
Goldman, C.; Judson, M.A. Corticosteroid refractory sarcoidosis. Respir. Med., 2020, 171, 106081.
[http://dx.doi.org/10.1016/j.rmed.2020.106081] [PMID: 32658838]
[102]
Extrapulmonary sarcoidosis. seminars in respiratory and critical care medicineThieme Medical Publishers, Inc.: 333 Seventh Avenue,. 2007.
[103]
Schutt, A.C.; Bullington, W.M.; Judson, M.A. Pharmacotherapy for pulmonary sarcoidosis: A Delphi consensus study. Respir. Med., 2010, 104(5), 717-723.
[http://dx.doi.org/10.1016/j.rmed.2009.12.009] [PMID: 20089389]
[104]
Pande, A.; Culver, D.A. Knowing when to use steroids, immunosuppressants or biologics for the treatment of sarcoidosis. Expert Rev. Respir. Med., 2020, 14(3), 285-298.
[http://dx.doi.org/10.1080/17476348.2020.1707672] [PMID: 31868547]
[105]
Adler, B.L.; Wang, C.J.; Bui, T-L.; Schilperoort, H.M.; Armstrong, A.W., Eds.; Anti-tumor necrosis factor agents in sarcoidosis: A systema-tic review of efficacy and safety. Seminars in arthritis and rheumatism; Elsevier, 2019.
[106]
Melani, A.S.; Bigliazzi, C.; Cimmino, F.A.; Bergantini, L.; Bargagli, E. A comprehensive review of sarcoidosis treatment for pulmonolo-gists. Pulm. Ther., 2021, 1-20.
[PMID: 34143362]

Rights & Permissions Print Cite
Article Metrics
25
© 2024 Bentham Science Publishers | Privacy Policy